HUTCHMED (LSE:HCM), the AIM-quoted biopharmaceutical company, said on 29 October 2026 that the US Food and Drug Administration has granted Orphan Drug Designation to sovleplenib, its oral Syk inhibitor, for primary immune thrombocytopenia, adding a US regulatory milestone while applications for the drug remain under review in China.

What HUTCHMED announced about sovleplenib

In an announcement released at 07:00 on 29 October 2026, HUTCHMED said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (ITP). The company said the designation "underscores the potential of sovleplenib to address significant unmet medical needs".

Sovleplenib is described as a novel, selective, oral inhibitor of spleen tyrosine kinase (Syk), taken once daily. HUTCHMED noted that Syk is an established target for B-cell lymphomas and autoimmune disorders, and said it currently retains all rights to sovleplenib worldwide. The release did not include comments from named executives or set out US development plans.

What orphan drug designation means

The FDA's Orphan Drug Designation programme applies to drugs and biologics for rare diseases affecting fewer than 200,000 people in the United States. According to the announcement, if sovleplenib is approved by the FDA for the designated indication, it would be eligible for seven years of US market exclusivity.

Other benefits listed by HUTCHMED include tax credits for qualified clinical trials, waivers of user fees under the Prescription Drug User Fee Act and specialised regulatory guidance from the FDA during development. The designation does not itself constitute approval, and the benefits apply only if the drug is approved for ITP.

Background on immune thrombocytopenia

HUTCHMED (LSE:HCM) described ITP as an autoimmune disorder in which platelets are destroyed and platelet production is reduced, increasing the risk of bleeding and bruising. The release said fatigue is reported in up to 39% of adults with the condition.

The company cited an incidence of 3.3 per 100,000 adults per year and a prevalence of 9.5 per 100,000 adults. It estimated around 110,000 patients in China and around 56,000 across the US, Germany, France, Italy, Spain, the UK and Japan, with up to 145,000 patients with chronic ITP in major markets excluding China.

Regulatory context in China and wider pipeline

In China, New Drug Applications for sovleplenib are under review by the National Medical Products Administration for primary ITP and for warm antibody autoimmune hemolytic anaemia. HUTCHMED said these are supported by positive data from the pivotal ESLIM-01 and ESLIM-02 trials in China, respectively. The announcement did not give a timetable for decisions.

HUTCHMED describes itself as a commercial-stage company focused on cancer and immunological diseases. Its first four medicines are marketed in China, and the first of these is also approved in markets including the US, Europe and Japan. The company is listed on Nasdaq and AIM, under the code HCM, and on the Hong Kong Stock Exchange.

Risks for investors in AIM stocks

Orphan status provides incentives but does not ensure approval or commercial success. HUTCHMED's own forward-looking statements caution that "Forward-looking statements involve risks and uncertainties", including assumptions about the timing and outcome of clinical studies. Regulatory outcomes in China and any future US pathway remain uncertain, and no US development timetable was provided.

What investors may watch next for HUTCHMED

The FDA decision gives sovleplenib a defined set of US incentives in a rare autoimmune indication, alongside regulatory reviews already under way in China. Market participants following AIM stocks and the wider UK stock market may look for NMPA decisions on the two Chinese applications, any announcement of US clinical plans for sovleplenib in ITP, and whether HUTCHMED pursues partnering for a drug to which it holds all global rights.